Skip to main content
Top
Published in: Immunologic Research 1/2017

01-02-2017 | Environment and Autoimmunity

Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil

Authors: Rotem Inbar, Ronen Weiss, Lucija Tomljenovic, Maria-Teresa Arango, Yael Deri, Christopher A. Shaw, Joab Chapman, Miri Blank, Yehuda Shoenfeld

Published in: Immunologic Research | Issue 1/2017

Login to get access

Abstract

Vaccine adjuvants and vaccines may induce autoimmune and inflammatory manifestations in susceptible individuals. To date most human vaccine trials utilize aluminum (Al) adjuvants as placebos despite much evidence showing that Al in vaccine-relevant exposures can be toxic to humans and animals. We sought to evaluate the effects of Al adjuvant and the HPV vaccine Gardasil versus the true placebo on behavioral and inflammatory parameters in female mice. Six-week-old C57BL/6 female mice were injected with either, Gardasil, Gardasil + pertussis toxin (Pt), Al hydroxide, or, vehicle control in amounts equivalent to human exposure. At 7.5 months of age, Gardasil and Al-injected mice spent significantly more time floating in the forced swimming test (FST) in comparison with vehicle-injected mice (Al, p = 0.009; Gardasil, p = 0.025; Gardasil + Pt, p = 0.005). The increase in floating time was already highly significant at 4.5 months of age for the Gardasil and Gardasil + Pt group (p ≤ 0.0001). No significant differences were observed in the number of stairs climbed in the staircase test which measures locomotor activity. These results indicate that differences observed in the FST were unlikely due to locomotor dysfunction, but rather due to depression. Moreover, anti-HPV antibodies from the sera of Gardasil and Gardasil + Pt-injected mice showed cross-reactivity with the mouse brain protein extract. Immunohistochemistry analysis revealed microglial activation in the CA1 area of the hippocampus of Gardasil-injected mice. It appears that Gardasil via its Al adjuvant and HPV antigens has the ability to trigger neuroinflammation and autoimmune reactions, further leading to behavioral changes.
Literature
1.
5.
14.
go back to reference Li X, et al. Glia activation induced by peripheral administration of aluminum oxide nanoparticles in rat brains. Nanomedicine. 2009;5(4):473–9.CrossRefPubMed Li X, et al. Glia activation induced by peripheral administration of aluminum oxide nanoparticles in rat brains. Nanomedicine. 2009;5(4):473–9.CrossRefPubMed
17.
go back to reference Eldred BE, et al. Vaccine components and constituents: responding to consumer concerns. Med J Aust. 2006;184(4):170–5.PubMed Eldred BE, et al. Vaccine components and constituents: responding to consumer concerns. Med J Aust. 2006;184(4):170–5.PubMed
18.
go back to reference Shoenfeld Y, et al. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol. 2000;18(2):181–4.PubMed Shoenfeld Y, et al. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol. 2000;18(2):181–4.PubMed
22.
go back to reference Munoz N, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57. doi:10.1016/S0140-6736(09)60691-7.CrossRefPubMed Munoz N, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57. doi:10.​1016/​S0140-6736(09)60691-7.CrossRefPubMed
24.
go back to reference Tordera RM, et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci. 2007;25:281–90.CrossRefPubMed Tordera RM, et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci. 2007;25:281–90.CrossRefPubMed
25.
go back to reference Katzav A, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001;10:496–9.CrossRefPubMed Katzav A, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001;10:496–9.CrossRefPubMed
26.
go back to reference Brown JA, et al. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Human Mol Genet. 2010;19(22):4515–28.CrossRef Brown JA, et al. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Human Mol Genet. 2010;19(22):4515–28.CrossRef
27.
go back to reference Harper DM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–55. doi:10.1016/S0140-6736(06)68439-0.CrossRefPubMed Harper DM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–55. doi:10.​1016/​S0140-6736(06)68439-0.CrossRefPubMed
28.
go back to reference Villa LL, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8. doi:10.1016/S1470-2045(05)70101-7.CrossRefPubMed Villa LL, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8. doi:10.​1016/​S1470-2045(05)70101-7.CrossRefPubMed
38.
40.
go back to reference Offit PA, Jew RK. Addressing parents’ concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 2003;112(6 Pt 1):1394–7.CrossRefPubMed Offit PA, Jew RK. Addressing parents’ concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 2003;112(6 Pt 1):1394–7.CrossRefPubMed
42.
go back to reference Gherardi RK, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001;124(Pt 9):1821–31.CrossRefPubMed Gherardi RK, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001;124(Pt 9):1821–31.CrossRefPubMed
43.
go back to reference Lee SH. Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after Gardasil® vaccination—a case report. Adv Biosci Biotech. 2012;3:1214–24.CrossRef Lee SH. Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after Gardasil® vaccination—a case report. Adv Biosci Biotech. 2012;3:1214–24.CrossRef
45.
go back to reference Xiu C, et al. Aluminum chloride- and norepinephrine-induced immunotoxicity on splenic lymphocytes by activating beta-AR/cAMP/PKA/NF-kappaB signal pathway in rats. Biol Trace Elem Res. 2014;162(1–3):168–74. doi:10.1007/s12011-014-0149-7.CrossRefPubMed Xiu C, et al. Aluminum chloride- and norepinephrine-induced immunotoxicity on splenic lymphocytes by activating beta-AR/cAMP/PKA/NF-kappaB signal pathway in rats. Biol Trace Elem Res. 2014;162(1–3):168–74. doi:10.​1007/​s12011-014-0149-7.CrossRefPubMed
46.
go back to reference Caulfield MJ, et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Human Vaccin. 2007;3(4):139–45.CrossRef Caulfield MJ, et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Human Vaccin. 2007;3(4):139–45.CrossRef
47.
go back to reference FDA. Food and Drug Administration. Inside clinical trials: testing medical products in people. (2009). FDA. Food and Drug Administration. Inside clinical trials: testing medical products in people. (2009).
48.
go back to reference Kanduc D. Potential cross-reactivity between HPV16 L1 protein and sudden death-associated antigens. J Exp Ther Oncol. 2011;9(2):159–65.PubMed Kanduc D. Potential cross-reactivity between HPV16 L1 protein and sudden death-associated antigens. J Exp Ther Oncol. 2011;9(2):159–65.PubMed
50.
go back to reference Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol. 2009;8(1):65–76.PubMed Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol. 2009;8(1):65–76.PubMed
52.
go back to reference Mendoza Plasencia Z, et al. Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus. Neurologia. 2010;25(1):58–9.CrossRefPubMed Mendoza Plasencia Z, et al. Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus. Neurologia. 2010;25(1):58–9.CrossRefPubMed
54.
go back to reference Sutton I, et al. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15(1):116–9.CrossRefPubMed Sutton I, et al. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15(1):116–9.CrossRefPubMed
59.
go back to reference Alvarez-Soria MJ, et al. Trastornos neurológicos desmielinizantes y vacunación del papilomavirus humano. Rev Neurol. 2011;52(8):472–6.PubMed Alvarez-Soria MJ, et al. Trastornos neurológicos desmielinizantes y vacunación del papilomavirus humano. Rev Neurol. 2011;52(8):472–6.PubMed
63.
go back to reference Kinoshita T, et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53(19):2185–200.CrossRefPubMed Kinoshita T, et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53(19):2185–200.CrossRefPubMed
66.
go back to reference Tomljenovic L, et al. Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the “autoimmune/autoinflammatory syndrome induced by adjuvants”: case report and literature review. J Investig Med High Impact Case Rep. 2014;. doi:10.1177/2324709614527812.PubMedPubMedCentral Tomljenovic L, et al. Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the “autoimmune/autoinflammatory syndrome induced by adjuvants”: case report and literature review. J Investig Med High Impact Case Rep. 2014;. doi:10.​1177/​2324709614527812​.PubMedPubMedCentral
69.
go back to reference Colafrancesco S, et al. HPV vaccines and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Am J Reprod Immunol. 2013;70(4):309–16.CrossRefPubMed Colafrancesco S, et al. HPV vaccines and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Am J Reprod Immunol. 2013;70(4):309–16.CrossRefPubMed
74.
go back to reference Das A, et al. Pancreatitis following human papillomavirus vaccination. Med J Aust. 2008;189(3):178.PubMed Das A, et al. Pancreatitis following human papillomavirus vaccination. Med J Aust. 2008;189(3):178.PubMed
77.
go back to reference Anaya JM, et al. Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine. Clin Exp Rheumatol. 2015;33(4):545–8.PubMed Anaya JM, et al. Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine. Clin Exp Rheumatol. 2015;33(4):545–8.PubMed
Metadata
Title
Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil
Authors
Rotem Inbar
Ronen Weiss
Lucija Tomljenovic
Maria-Teresa Arango
Yael Deri
Christopher A. Shaw
Joab Chapman
Miri Blank
Yehuda Shoenfeld
Publication date
01-02-2017
Publisher
Springer US
Published in
Immunologic Research / Issue 1/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8826-6

Other articles of this Issue 1/2017

Immunologic Research 1/2017 Go to the issue